WO2000070017A3 - Methods using of fab i and compounds modulating fab i activity - Google Patents

Methods using of fab i and compounds modulating fab i activity Download PDF

Info

Publication number
WO2000070017A3
WO2000070017A3 PCT/US2000/012104 US0012104W WO0070017A3 WO 2000070017 A3 WO2000070017 A3 WO 2000070017A3 US 0012104 W US0012104 W US 0012104W WO 0070017 A3 WO0070017 A3 WO 0070017A3
Authority
WO
WIPO (PCT)
Prior art keywords
fab
disclosed
methods
polypeptides
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/012104
Other languages
French (fr)
Other versions
WO2000070017A2 (en
Inventor
Walter E Dewolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Priority to EP00935862A priority Critical patent/EP1180164A4/en
Priority to JP2000618423A priority patent/JP2002544291A/en
Publication of WO2000070017A2 publication Critical patent/WO2000070017A2/en
Publication of WO2000070017A3 publication Critical patent/WO2000070017A3/en
Anticipated expiration legal-status Critical
Priority to US10/888,524 priority patent/US20050112713A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Prokayrotic FAB I polypeptides and DNA (RNA) encoding such FAB I and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FAB I for the treatment of infection, such as bacterial infections. Antagonists against such FAB I and their use as a therapeutic to treat /infections, such as staphylococcal infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of FAB I nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding FAB I and for detecting the polypeptide in a host.
PCT/US2000/012104 1996-08-28 2000-05-04 Methods using of fab i and compounds modulating fab i activity Ceased WO2000070017A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00935862A EP1180164A4 (en) 1999-05-14 2000-05-04 METHODS USING FAB I COMPOUNDS AND COMPOUNDS THAT MODULATE FAB I ACTIVITY
JP2000618423A JP2002544291A (en) 1999-05-14 2000-05-04 How to use FABI
US10/888,524 US20050112713A1 (en) 1996-08-28 2004-07-09 Methods of using Fab I and compounds modulating Fab I activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13436299P 1999-05-14 1999-05-14
US60/134,362 1999-05-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/888,524 Continuation-In-Part US20050112713A1 (en) 1996-08-28 2004-07-09 Methods of using Fab I and compounds modulating Fab I activity

Publications (2)

Publication Number Publication Date
WO2000070017A2 WO2000070017A2 (en) 2000-11-23
WO2000070017A3 true WO2000070017A3 (en) 2001-02-08

Family

ID=22463029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012104 Ceased WO2000070017A2 (en) 1996-08-28 2000-05-04 Methods using of fab i and compounds modulating fab i activity

Country Status (3)

Country Link
EP (1) EP1180164A4 (en)
JP (1) JP2002544291A (en)
WO (1) WO2000070017A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010881A (en) 1996-02-20 2000-01-04 Smithkline Beecham Corporation RibG
WO1998006734A1 (en) 1996-08-16 1998-02-19 Smithkline Beecham Corporation Novel prokaryotic polynucleotides, polypeptides and their uses
US6995254B1 (en) 1996-08-28 2006-02-07 Affinium Pharmaceuticals, Inc. Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I
US6951729B1 (en) 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
US7048926B2 (en) 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
CA2532024A1 (en) 2003-07-11 2005-01-20 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from staphylococcus aureus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826774A2 (en) * 1996-08-28 1998-03-04 Smithkline Beecham Corporation Staphylococcal Fab I enoyl-ACP reductase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826774A2 (en) * 1996-08-28 1998-03-04 Smithkline Beecham Corporation Staphylococcal Fab I enoyl-ACP reductase
JPH10174590A (en) * 1996-08-28 1998-06-30 Smithkline Beecham Corp FAB I

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERGLER H. ET AL.: "Protein EnvM is the NADH-dependent enoyl-ACP reductase (FabI) of escherichia coli", J. BIOL. CHEM., vol. 269, no. 8, 25 February 1994 (1994-02-25), pages 5493 - 5496, XP002933508 *
See also references of EP1180164A4 *

Also Published As

Publication number Publication date
JP2002544291A (en) 2002-12-24
EP1180164A2 (en) 2002-02-20
EP1180164A4 (en) 2002-11-27
WO2000070017A2 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
EP0837131A3 (en) Staphylococcus fibronectin binding protein compounds
EP0837138A3 (en) Novel topoisomerase III
WO2001034809A3 (en) Staphylococcus epidermidis nucleic acids and proteins
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
EP0826774A3 (en) Staphylococcal Fab I enoyl-ACP reductase
EP0837130A3 (en) M protein analogue from Streptococcus pneumoniae
WO2003080856A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP0837137A3 (en) Novel topoisomerase III
EP0835938A3 (en) Topoisomerase I
EP0837136A3 (en) Novel topoisomerase I
EP0834568A3 (en) Novel saliva binding protein
WO2000070017A3 (en) Methods using of fab i and compounds modulating fab i activity
EP0845535A3 (en) Leader peptidase (lep) from Streptococcus
WO2001029217A3 (en) Novel polypeptides and polynucleotides encoding same
EP0843016A3 (en) Staphylococcus FabD (malonylCoA:ACP transacylase) protein
EP0839910A3 (en) Spo-rel, a Staphylococcus relA/spot homologue
WO2003029423A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP0808899A3 (en) Human marco scavenger receptor (HMarcoSR)
WO2001064876A3 (en) Human schizophrenia gene
EP0843011A3 (en) RsbU-1 derived from Staphylococcus
WO2003085124A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP0845531A3 (en) Polypeptides and polynucleotides from the Staphylococcus SigB operon
EP0846766A3 (en) IgA Fc binding protein from Streptococcus pneumoniae
EP0838523A3 (en) RsbW-1 derived from Staphylococcus
EP0816502A3 (en) Mur A-1, an UDP-N-acetylglucosamine enolpyruvyl-transferase from Streptococcus pneumoniae

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10009219

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000935862

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 618423

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000935862

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000935862

Country of ref document: EP